Skip to search formSkip to main contentSkip to account menu

Anti-prolactin Receptor Antibody LFA102

Known as: LFA102 
A neutralizing antibody against the prolactin receptor (PRLR) with potential antineoplastic activity. Upon administration, anti-prolactin receptor… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge.
Highly Cited
2016
Highly Cited
2016
Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer
Lessons Learned Despite evidence for a role for prolactin signaling in breast and prostate tumorigenesis, a prolactin receptor… 
2016
2016
Targeting Prolactin Receptor (PRLR) Signaling in PRLR-Positive Breast and Prostate Cancer
In this issue of The Oncologist, Agarwal et al. report negative results from a phase I trial of LFA102. Although “negative” in… 
2013
2013
Molecular Pathways Molecular Pathways : Blockade of the PRLR Signaling Pathway as a Novel Antihormonal Approach for the Treatment of Breast and Prostate Cancer
The prolactin (PRL)–prolactin receptor (PRLR) signaling complex has been implicated in the pathology of breast and prostate… 
Highly Cited
2012
Highly Cited
2012
Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer
Numerous lines of evidence suggest that the polypeptide hormone prolactin (PRL) may contribute to breast and prostate… 
2011
2011
Abstract DDT02-02: Preclinical development of LFA102, a highly potent and selective neutralizing antibody against the prolactin receptor
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL The prolactin receptor (PRLR) is a class I cytokine… 
2011
2011
P3-17-09: Neutralizing the Prolactin Receptor with Therapeutic Antibody LFA102: A Novel Approach for the Treatment of Breast Cancer.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)